The only way we have to improve on current medical treatments and save children’ lives is to develop better tools to fight childhood cancer.
What differentiate aPODD is that we are drug development experts driven by patients' needs
We fill the gaps and act as catalyst for innovation. We create synergies by bringing together industry and academia to remove barriers and accelerate the development of better medicines for children with cancer
Cancer is the leading cause of death by disease for children in Europe and North America.
Despite significant improvements in the treatment of certain childhood cancers, for some very aggressive diseases we have not seen any improvement over the past 20-30 years and too many children still face a very poor prognosis.
Every 3 minutes a child is diagnosed with cancer across the world and in Europe alone up to 6,000 children and adolescents die of cancer every year.
Childhood cancers are generally different from those affecting adults.
Because of the smaller number of patients, the pharmaceutical industry does not develop specific medicines for children, focusing insterad on the more common adult cancers. Children can hardly benefit from the latest development in cancer research.
When it comes to the development of new medicines, children are treated as second-class citizens.